
浏览全部资源
扫码关注微信
纸质出版日期:2013
移动端阅览
尹继旺. 葶苈大枣泻肺汤合导痰汤联合化疗治疗痰瘀阻肺型肺癌[J]. 中国实验方剂学杂志, 2013,19(16):331-335.
YIN Ji-wang. Clinical Observation on Homemade Lung Cancer Prescription in Treatment of Tanyu Zufei Type Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(16): 331-335.
尹继旺. 葶苈大枣泻肺汤合导痰汤联合化疗治疗痰瘀阻肺型肺癌[J]. 中国实验方剂学杂志, 2013,19(16):331-335. DOI: 10.11653/syfj2013160331.
YIN Ji-wang. Clinical Observation on Homemade Lung Cancer Prescription in Treatment of Tanyu Zufei Type Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(16): 331-335. DOI: 10.11653/syfj2013160331.
目的: 观察葶苈大枣泻肺汤合导痰汤(简称肺癌方)联合化疗治疗痰瘀阻肺型肺癌的临床疗效。 方法: 将100例中晚期痰瘀阻肺型肺癌患者随机分为对照组和治疗组各50例。对照组仅采用西医方案化疗
治疗组在对照组的基础上同时给予中药肺癌方配合治疗。连续治疗3个月后
观察对照组和治疗组患者治疗前后近期疗效、生活质量改善、体质量变化、外周血象、免疫功能改善以及不良反应发生情况和患者治疗1
3
5年后的生存率。 结果: 治疗组和对照组总有效率分别为80.0%
50.0%
治疗组近期疗效明显优于对照组
呈显著性差异(P<0.05);治疗组和对照组患者生活质量提高率分别为70.0%
40.0%
治疗组明显优于对照组
呈显著性差异(P<0.05);治疗前后治疗组和对照组的体质量变化好转率分别为16.0%
20.0%
无统计学意义;治疗组出现外周血象异常情况明显低于对照组
具有显著性差异(P<0.05);治疗组与对照组治疗前后比较
CD4+
CD8+
CD4+/CD8+和NK细胞活性等免疫指标均呈现不同程度的显著性差异(P<0.05或P<0.01)
治疗组免疫力明显得到提高;与对照组比较
治疗组不良反应发生率明显低于对照组
呈现显著性差异(P<0.05);治疗组治疗1
3
5年后的生存率明显高于对照组
均呈现显著性差异(P<0.05)。 结论: 肺癌方联合化疗药物治疗痰瘀阻肺型中晚期肺癌能有效缓解患者临床症状
提高机体免疫力
减少毒副反应
提高生活质量
延长患者寿命
两者起到协同增效减毒效果
值得临床推广和应用。
Objective: To investigate the clinical efficacy of Tingli Dazao Xiefei decoction and Daotan soup on the Tanyu Zufei type lung cancer. Method: The one hundred cases of Tanyu Zufei type lung cancer in middle and late period were randomly divided into control group and treatment group
50 case. each group. The control group only used western medicine according to chemotherapy scheme
and the treatment groups were treated with lung cancer prescription based on the treatment of control group. After 3 months
the short term curative effect
the improvement of life quality
the changes of body weight
the improvement of peripheral blood and immune function
and the occurrence of adverse reaction and the survival rates of patients after 1
3 and 5 years' treatment were observed. Result: The total effectiveness in control group and treatment group was 80.0% and 50.0%
respectively
the short term curative effect in treatment group was better than the control group
and there was significant difference(P<0.05);the improvement rate of life quality was 70.0% and 40.0%
respectively
the treatment group was better than the control group
and there was significant difference(P<0.05);the improvement rate of body weight was 16.0% and 20.0%
respectively
and there was no significant difference; the peripheral blood abnormality rates of treatment group was obviously lower than the control group
and there was significant difference(P<0.05);the treatment and control group were compared before and after treatment
the immune indexes (CD4+
CD8+
CD4+/CD8+and the activity of NK cell) all presented significant difference of different degree(P<0.05 and P<0.01)
and the immunity of treatment group was obviously improved; compared with control group
the occurrence rate of adverse reaction in treatment group was obviously lower than control group
and there was significant difference(P<0.05). The survival rates of patients after 1
3 and 5 years' treatment was better than the control group
and there was significant difference(P<0.05). Conclusion: The tanyuzufei type lung cancer was cured bylung cancer prescription combined with chemotherapy
and it could effectively relieve the clinical symptoms
improve the immunity
reduce the occurrence of adverse reaction
and improve the life quality
and the traditional Chinese medicine combined with chemotherapy has the efficacy and low toxicity.
0
浏览量
4
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621